Aurinia Pharmaceuticals AUPH Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's pre-tax income?
- Aurinia Pharmaceuticals (AUPH) reported pre-tax income of $43.93M in Q1 2026.
- How has Aurinia Pharmaceuticals's pre-tax income changed year-over-year?
- Aurinia Pharmaceuticals's pre-tax income increased by 80.4% year-over-year, from $24.35M to $43.93M.
- What is the long-term trend for Aurinia Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's pre-tax income has grown at a -10.8% compound annual growth rate (CAGR), from -$180.21M to $114.16M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.